Binimetinib – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 39 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Binimetinib - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Binimetinib is an orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2-dependent effector proteins and transcription factors, which may...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Binimetinib is an orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Binimetinib is an orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and inhibition in the production of various inflammatory cytokines including interleukin-1, -6, and tumor necrosis factor. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.

Binimetinib is a member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-fluorophenyl)nitrilo, and N-(2-hydroxyethyl)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor (IC50= 12 nM). Approved by the FDA for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation in combination with encorafenib. It has a role as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor, an antineoplastic agent, and an apoptosis inducer. It is a member of benzimidazoles, a member of bromobenzenes, a member of monofluorobenzenes, a hydroxamic acid ester, and a secondary amino compound.

Binimetinib, also known as Mektovi, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor that is combined with [Encorafenib]. On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.

Mechanism of Action

Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. The inhibition of MEK1/2 prevents the activation of MEK1/2-dependent effector proteins and transcription factors. This process can result in the inhibition of growth factor-mediated cell signaling. This may lead to the inhibition of tumor cell proliferation and inhibition in the production of various inflammatory cytokines including interleukin-1, -6, and tumor necrosis factor. MEK1/2 are themselves threonine and tyrosine kinases that possess a dual specificity. They subsequently contribute critically to the activation of the RAS/RAF/MEK/ERK pathway and are typically upregulated in a number of different tumor cell types.

Binimetinib is a MEK inhibitor. MEK is an enzyme that regulates the biosynthesis of the inflammatory cytokines TNF, IL-6 and IL-1. MEK inhibitors interfere with these biosynthetic processes. It is a chemotherapeutic agent that has anti-tumor activity

Indications

  • Food and Drug Administration approved encorafenib and binimetinib in combination with patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
  • Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
  • Treatment of colorectal carcinoma
  • Treatment of melanoma
  • Metastatic Melanoma
  • Unresectable Melanoma

Use in Cancer

Binimetinib is approved to be used with encorafenib to treat:

  • Melanoma that cannot be removed by surgery or has spread to other parts of the body. It is used in patients whose cancer has a certain mutation in the BRAF gene.

Binimetinib is also being studied in the treatment of other types of cancer.

Contraindications

  • chronic heart failure
  • blood clot formation in vein
  • bleeding
  • liver problems
  • a condition with muscle tissue breakdown called rhabdomyolysis
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • lung tissue problem

Dosage

Strengths: 15 mg

Melanoma – Metastatic

  • 45 mg orally every 12 hours in combination with encorafenib until disease progression or unacceptable toxicity
  • Refer to the encorafenib prescribing information for encorafenib dosing information.
  • This drug may be taken with or without food.
  • Do not take a missed dose within 6 hours of the next dose.
  • Do not take an additional dose if vomiting occurs after administration but continue with the next scheduled dose.

Liver Dose Adjustments

  • Mild hepatic impairment (total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin greater than 1 and less than or equal to 1.5 x the upper limit of normal (ULN) and any AST or total bilirubin less than or equal to ULN and AST greater than ULN: No adjustment recommended.
  • Moderate (total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin greater than 1.5 and less than or equal to 3 × ULN and any AST) or severe (total bilirubin levels greater than or equal to 3 × ULN and any AST) hepatic impairment: The recommended dose is 30 mg orally 2 times a day.

Dose Adjustments

If encorafenib is permanently discontinued, discontinue this drug.
Recommended Dose Reductions for Adverse Reactions:

  • First dose reduction: 30 mg orally every 12 hours
  • Subsequent modification: Permanently discontinue this drug if unable to tolerate 30 mg orally every 12 hours.

DOSE ADJUSTMENTS:
CARDIOMYOPATHY:

  • Asymptomatic, absolute decrease in LVEF of greater than 10% from baseline that is also below lower limit of normal (LLN): Withhold this drug for up to 4 weeks; evaluate LVEF every 2 weeks. Resume this drug at a reduced dose if LVEF is at or above the lower limit or normal AND absolute decrease from baseline is 10% or less AND patient is asymptomatic. If the LVEF does not recover within 4 weeks permanently discontinue this drug.
  • Symptomatic congestive heart failure or absolute decrease in LVEF or greater than 20% from baseline that is also below LLN: Permanently discontinue this drug.

VENOUS THROMBOEMBOLISM:

  • Uncomplicated deep venous thrombosis (DVT) or pulmonary embolism (PE): Withhold this drug. If improves to Grade 0 or 1, resume at a reduced dose. If no improvement, permanently discontinue this drug.
  • Life-threatening PE: Permanently discontinue this drug.

SEROUS RETINOPATHY:

  • Symptomatic serous retinopathy/retinal pigment epithelial detachments: Withhold this drug for up to 10 days. If improves and becomes asymptomatic, resume at the same dose. If not improved, resume at a lower dose level or permanently discontinue this drug.

RETINAL VEIN OCCLUSION (RVO):

  • Any grade: Permanently discontinue this drug.

UVEITIS:

  • Grade 1, 2, or 3: If Grade 1 or 2 does not respond to specific ocular therapy, or for Grade 3 uveitis, withhold this drug for up to 6 weeks. If improved, resume at same or reduced dose. If not improved, permanently discontinue this drug.
  • Grade 4: Permanently discontinue this drug.

INTERSTITIAL LUNG DISEASE:

  • Grade 2: Withhold this drug for up to 4 weeks. If improved to Grade 0 or 1, resume a reduced dose. If not resolved within 4 weeks, permanently discontinue this drug.
  • Grade 3 or 4: Permanently discontinue this drug.

HEPATOTOXICITY:

  • Grade 2 AST or ALT increased: Maintain the dose. If no improvement within 2 weeks, withhold this drug until improved to Grade 0 or 1 or to pretreatment/baseline levels and then resume at the same dose.
  • First occurrence of Grade 3 AST or ALT increased: Withhold this drug for up to 4 weeks. If improves to Grade 0 or 1 or to pretreatment/baseline levels, resume at reduced dose. If no improvement, permanently discontinue this drug.
  • Recurrent Grade 3 AST or ALT increased: Consider permanently discontinuing this drug.
  • First occurrence of Grade 4 AST or ALT increased: Permanently discontinue this drug OR withhold this drug for up to 4 weeks. If improves to Grade 0 or 1 or to pretreatment/baseline levels, then resume at a reduced dose. If no improvement, permanently discontinue this drug.
  • Recurrent Grade 4 AST or ALT increased: Permanently discontinue this drug.

RHABDOMYOLYSIS OR CREATINE PHOSPHOKINASE (CPK) ELEVATIONS:

  • Grade 4 asymptomatic CPK elevation OR any Grade CPK elevation with symptoms or with renal impairment: Withhold this drug for up to 4 weeks. If improved to Grade 0 or 1 resume at a reduced dose. If not resolved within 4 weeks, permanently discontinue this drug.

DERMATOLOGIC:

  • Grade 2: If no improvement within 2 weeks, withhold this drug until Grades 0 to 1. Resume at the same dose if the first occurrence or reduce the dose if recurrent.
  • Grade 3: Withhold this drug until Grade 0 or 1. Resume at the same dose if the first occurrence or reduce dose if recurrent.
  • Grade 4: Permanently discontinue this drug.

OTHER ADVERSE REACTIONS (INCLUDING HEMORRHAGE):

  • Recurrent Grade 2 or first occurrence of any Grade 3: Withhold this drug for up to 4 weeks. If improved to Grade 0 or 1 resume at a reduced dose. If not resolved within 4 weeks, permanently discontinue this drug.
  • The first occurrence of any Grade 4: Permanently discontinue this drug OR withhold this drug for up to 4 weeks. If improves to Grade 0 or 1 or to pretreatment/baseline levels, then resume at a reduced dose. If no improvement, permanently discontinue this drug.

Side Effects

The Most Common

  • fatigue, nausea, diarrhea, vomiting,
  • abdominal pain, and arthralgia.
  • hemorrhage and pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache.
  • Retinal hemorrhage, retinal detachment (6%),
  • macular edema, serous retinopathy (20%)
  • Hypertension,
  • thromboembolic events such as DVT, resulting in pulmonary embolism (5.6%),
  • peripheral edema or periorbital edema (43.5%),
  • hemorrhage (11.2%)
  • Pulmonary events
  • Pneumonitis (1.9%),
  • Pulmonary embolism
  • Cardiovascular system QT interval prolongation (3.3%),
  • Left ventricular dysfunction (7%)
  • Gastrointestinal system
  • Hepatotoxicity, diarrhea, nausea, vomiting,
  • stomatitis, dry mouth
  • Acneiform dermatitis

More Common

  • fatigue
  • nausea
  • diarrhea
  • vomiting
  • abdominal pain
  • constipation
  • dizziness
  • vision changes or eye pain, swelling, or redness
  • fever, sore throat, chills, cough, or other signs of infection
  • yellow eyes or skin, dark urine, loss of appetite, fatigue, or pain or discomfort in right upper stomach area
  • unusual weakness, muscle pain, or dark red or brown urine
  • unusual bleeding or bruising; black, tarry, or bloody stools; or coughing up blood
  • shortness of breath or cough
  • sudden onset of difficulty breathing; chest pain; swelling of the feet, ankles, or lower legs; or leg pain, warmth, or swelling
  • fast, pounding heartbeat; shortness of breath; swelling of ankles and feet; or dizziness

Rare

  • Anemia
  • Vomiting
  • Increased AST/ALT
  • Abdominal pain
  • Constipation
  • Rash
  • Increased alkaline phosphatase
  • Visual impairment
  • Serous retinopathy/retinal pigment epithelial dystrophy (RPED)
  • Bleeding
  • Low blood sodium (hyponatremia)
  • Fever
  • Dizziness
  • Low white blood cell count (leukopenia, neutropenia)
  • Low lymphocyte levels (lymphopenia)
  • Swelling of extremities
  • Increased GGT
  • High blood pressure (hypertension)
  • Colitis
  • Panniculitis
  • Drug hypersensitivity

Drug interaction

Pregnancy and Lactation

US FDA pregnancy category Not Assigned

Pregnancy

Drugs that have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.

The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help healthcare providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

Lactation

No information is available on the use of this drug during breastfeeding. Because it is highly bound to plasma proteins, and the half-life is 3.5 hours, the amount in milk is likely to be low; however, the manufacturer recommends that breastfeeding be discontinued during therapy and for at least 3 days after. For patients taking the combination with encorafenib, the manufacturer recommends that breastfeeding be discontinued during therapy and for at least 2 weeks after.

How should this medicine be used?

Binimetinib comes as a tablet to take by mouth. It is usually taken with or without food twice daily, approximately 12 hours apart. Take binimetinib at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take binimetinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

If you vomit after taking the medication, do not take another dose. Continue your regular dosing schedule.

Your doctor may decrease or temporarily or permanently stop your treatment depending on if you experience any side effects. Be sure to tell your doctor how you are feeling during your treatment with binimetinib.

Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

What special precautions should I follow?

Before taking binimetinib,

  • tell your doctor and pharmacist if you are allergic to binimetinib, any other medications, or any of the ingredients in binimetinib tablets. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor if you have or have ever had heart or liver disease.
  • tell your doctor if you are pregnant or plan to become pregnant. You will have to take a pregnancy test before starting treatment. You should use birth control to prevent pregnancy during your treatment with binimetinib and for 30 days after your final dose. Talk to your doctor about methods of birth control that will work for you. If you become pregnant while taking binimetinib, call your doctor immediately. Binimetinib may harm the fetus.
  • tell your doctor if you are breastfeeding. Do not breastfeed while you are taking binimetinib and for 3 days after your final dose.

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Binimetinib – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. The inhibition of MEK1/2 prevents the activation of MEK1/2-dependent effector proteins and transcription factors. This process can result in the inhibition of growth factor-mediated cell signaling. This may lead to the inhibition of tumor cell proliferation and inhibition in the production of various inflammatory cytokines including interleukin-1, -6, and tumor necrosis factor. MEK1/2 are themselves threonine and tyrosine kinases that possess a dual specificity. They subsequently contribute critically to the activation of the RAS/RAF/MEK/ERK pathway and are typically upregulated in a number of different tumor cell types. Binimetinib is a MEK inhibitor. MEK is an enzyme that regulates the biosynthesis of the inflammatory cytokines TNF, IL-6 and IL-1. MEK inhibitors interfere with these biosynthetic processes. It is a chemotherapeutic agent that has anti-tumor activity Indications Food and Drug Administration approved encorafenib and binimetinib in combination with patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Treatment of colorectal carcinoma Treatment of melanoma Metastatic Melanoma Unresectable Melanoma Use in Cancer Binimetinib is approved to be used with encorafenib to treat: Melanoma that cannot be removed by surgery or has spread to other parts of the body. It is used in patients whose cancer has a certain mutation in the BRAF gene. Binimetinib is also being studied in the treatment of other types of cancer. Contraindications chronic heart failure blood clot formation in vein bleeding liver problems a condition with muscle tissue breakdown called rhabdomyolysis pregnancy a patient who is producing milk and breastfeeding lung tissue problem Dosage Strengths: 15 mg Melanoma - Metastatic 45 mg orally every 12 hours in combination with encorafenib until disease progression or unacceptable toxicity Refer to the encorafenib prescribing information for encorafenib dosing information. This drug may be taken with or without food. Do not take a missed dose within 6 hours of the next dose. Do not take an additional dose if vomiting occurs after administration but continue with the next scheduled dose. Liver Dose Adjustments Mild hepatic impairment (total bilirubin greater than 1 and less than or equal to 1.5 x the upper limit of normal (ULN) and any AST or total bilirubin less than or equal to ULN and AST greater than ULN: No adjustment recommended. Moderate (total bilirubin greater than 1.5 and less than or equal to 3 × ULN and any AST) or severe (total bilirubin levels greater than or equal to 3 × ULN and any AST) hepatic impairment: The recommended dose is 30 mg orally 2 times a day. Dose Adjustments If encorafenib is permanently discontinued, discontinue this drug. Recommended Dose Reductions for Adverse Reactions: First dose reduction: 30 mg orally every 12 hours Subsequent modification: Permanently discontinue this drug if unable to tolerate 30 mg orally every 12 hours. DOSE ADJUSTMENTS: CARDIOMYOPATHY: Asymptomatic, absolute decrease in LVEF of greater than 10% from baseline that is also below lower limit of normal (LLN): Withhold this drug for up to 4 weeks; evaluate LVEF every 2 weeks. Resume this drug at a reduced dose if LVEF is at or above the lower limit or normal AND absolute decrease from baseline is 10% or less AND patient is asymptomatic. If the LVEF does not recover within 4 weeks permanently discontinue this drug. Symptomatic congestive heart failure or absolute decrease in LVEF or greater than 20% from baseline that is also below LLN: Permanently discontinue this drug. VENOUS THROMBOEMBOLISM: Uncomplicated deep venous thrombosis (DVT) or pulmonary embolism (PE): Withhold this drug. If improves to Grade 0 or 1, resume at a reduced dose. If no improvement, permanently discontinue this drug. Life-threatening PE: Permanently discontinue this drug. SEROUS RETINOPATHY: Symptomatic serous retinopathy/retinal pigment epithelial detachments: Withhold this drug for up to 10 days. If improves and becomes asymptomatic, resume at the same dose. If not improved, resume at a lower dose level or permanently discontinue this drug. RETINAL VEIN OCCLUSION (RVO): Any grade: Permanently discontinue this drug. UVEITIS: Grade 1, 2, or 3: If Grade 1 or 2 does not respond to specific ocular therapy, or for Grade 3 uveitis, withhold this drug for up to 6 weeks. If improved, resume at same or reduced dose. If not improved, permanently discontinue this drug. Grade 4: Permanently discontinue this drug. INTERSTITIAL LUNG DISEASE: Grade 2: Withhold this drug for up to 4 weeks. If improved to Grade 0 or 1, resume a reduced dose. If not resolved within 4 weeks, permanently discontinue this drug. Grade 3 or 4: Permanently discontinue this drug. HEPATOTOXICITY: Grade 2 AST or ALT increased: Maintain the dose. If no improvement within 2 weeks, withhold this drug until improved to Grade 0 or 1 or to pretreatment/baseline levels and then resume at the same dose. First occurrence of Grade 3 AST or ALT increased: Withhold this drug for up to 4 weeks. If improves to Grade 0 or 1 or to pretreatment/baseline levels, resume at reduced dose. If no improvement, permanently discontinue this drug. Recurrent Grade 3 AST or ALT increased: Consider permanently discontinuing this drug. First occurrence of Grade 4 AST or ALT increased: Permanently discontinue this drug OR withhold this drug for up to 4 weeks. If improves to Grade 0 or 1 or to pretreatment/baseline levels, then resume at a reduced dose. If no improvement, permanently discontinue this drug. Recurrent Grade 4 AST or ALT increased: Permanently discontinue this drug. RHABDOMYOLYSIS OR CREATINE PHOSPHOKINASE (CPK) ELEVATIONS: Grade 4 asymptomatic CPK elevation OR any Grade CPK elevation with symptoms or with renal impairment: Withhold this drug for up to 4 weeks. If improved to Grade 0 or 1 resume at a reduced dose. If not resolved within 4 weeks, permanently discontinue this drug. DERMATOLOGIC: Grade 2: If no improvement within 2 weeks, withhold this drug until Grades 0 to 1. Resume at the same dose if the first occurrence or reduce the dose if recurrent. Grade 3: Withhold this drug until Grade 0 or 1. Resume at the same dose if the first occurrence or reduce dose if recurrent. Grade 4: Permanently discontinue this drug. OTHER ADVERSE REACTIONS (INCLUDING HEMORRHAGE): Recurrent Grade 2 or first occurrence of any Grade 3: Withhold this drug for up to 4 weeks. If improved to Grade 0 or 1 resume at a reduced dose. If not resolved within 4 weeks, permanently discontinue this drug. The first occurrence of any Grade 4: Permanently discontinue this drug OR withhold this drug for up to 4 weeks. If improves to Grade 0 or 1 or to pretreatment/baseline levels, then resume at a reduced dose. If no improvement, permanently discontinue this drug. Side Effects The Most Common fatigue, nausea, diarrhea, vomiting, abdominal pain, and arthralgia. hemorrhage and headache. Retinal hemorrhage, retinal detachment (6%), macular edema, serous retinopathy (20%) Hypertension, thromboembolic events such as DVT, resulting in pulmonary embolism (5.6%), peripheral edema or periorbital edema (43.5%), hemorrhage (11.2%) Pulmonary events Pneumonitis (1.9%), Pulmonary embolism Cardiovascular system QT interval prolongation (3.3%), Left ventricular dysfunction (7%) Gastrointestinal system Hepatotoxicity, diarrhea, nausea, vomiting, stomatitis, dry mouth Acneiform dermatitis More Common fatigue nausea diarrhea vomiting abdominal pain constipation dizziness vision changes or eye pain, swelling, or redness fever, sore throat, chills, cough, or other signs of infection yellow eyes or skin, dark urine, loss of appetite, fatigue, or pain or discomfort in right upper stomach area unusual weakness, muscle pain, or dark red or brown urine unusual bleeding or bruising; black, tarry, or bloody stools; or coughing up blood shortness of breath or cough sudden onset of difficulty breathing; chest pain; swelling of the feet, ankles, or lower legs; or leg pain, warmth, or swelling fast, pounding heartbeat; shortness of breath; swelling of ankles and feet; or dizziness Rare Anemia Vomiting Increased AST/ALT Abdominal pain Constipation Rash Increased alkaline phosphatase Visual impairment Serous retinopathy/retinal pigment epithelial dystrophy (RPED) Bleeding Low blood sodium (hyponatremia) Fever Dizziness Low white blood cell count (leukopenia, neutropenia) Low lymphocyte levels (lymphopenia) Swelling of extremities Increased GGT High blood pressure (hypertension) Colitis Panniculitis Drug hypersensitivity Drug interaction DRUG INTERACTION Abametapir The serum concentration of Binimetinib can be increased when it is combined with Abametapir. Abatacept The metabolism of Binimetinib can be increased when combined with Abatacept. Abiraterone The serum concentration of Binimetinib can be increased when it is combined with Abiraterone. Abrocitinib The serum concentration of Binimetinib can be increased when it is combined with Abrocitinib. Acenocoumarol The metabolism of Binimetinib can be decreased when combined with Acenocoumarol. Acetaminophen The metabolism of Binimetinib can be decreased when combined with Acetaminophen. Acyclovir The metabolism of Binimetinib can be decreased when combined with Acyclovir. Adalimumab The metabolism of Binimetinib can be increased when combined with Adalimumab. Adenine The metabolism of Binimetinib can be decreased when combined with Adenine. Afatinib The serum concentration of Binimetinib can be increased when it is combined with Afatinib. Agomelatine The metabolism of Binimetinib can be decreased when combined with Agomelatine. Albendazole The metabolism of Binimetinib can be increased when combined with Albendazole. Alosetron The metabolism of Binimetinib can be decreased when combined with Alosetron. Ambrisentan The serum concentration of Binimetinib can be increased when it is combined with Ambrisentan. Aminophenazone The metabolism of Binimetinib can be decreased when combined with Aminophenazone. Aminophylline The metabolism of Binimetinib can be decreased when combined with Aminophylline. Amiodarone The serum concentration of Binimetinib can be increased when it is combined with Amiodarone. Amitriptyline The metabolism of Binimetinib can be decreased when combined with Amitriptyline. Anagrelide The metabolism of Binimetinib can be decreased when combined with Anagrelide. Anakinra The metabolism of Binimetinib can be increased when combined with Anakinra. Antipyrine The metabolism of Binimetinib can be decreased when combined with Antipyrine. Apalutamide The serum concentration of Binimetinib can be decreased when it is combined with Apalutamide. Apixaban The serum concentration of Binimetinib can be increased when it is combined with Apixaban. Apremilast The metabolism of Binimetinib can be increased when combined with Apremilast. Armodafinil The metabolism of Binimetinib can be increased when combined with Armodafinil. Arsenic trioxide The serum concentration of Binimetinib can be increased when it is combined with Arsenic trioxide. Articaine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Articaine. Asciminib The serum concentration of Binimetinib can be increased when it is combined with Asciminib. Asenapine The metabolism of Binimetinib can be decreased when combined with Asenapine. Asunaprevir The serum concentration of Binimetinib can be increased when it is combined with Asunaprevir. Atazanavir The metabolism of Binimetinib can be decreased when combined with Atazanavir. Avanafil The serum concentration of Binimetinib can be increased when it is combined with Avanafil. Avatrombopag The serum concentration of Binimetinib can be increased when it is combined with Avatrombopag. Axitinib The metabolism of Binimetinib can be decreased when combined with Axitinib. Azathioprine The metabolism of Binimetinib can be decreased when combined with Azathioprine. Azelastine The metabolism of Binimetinib can be decreased when combined with Azelastine. Belantamab mafodotin The serum concentration of Binimetinib can be increased when it is combined with Belantamab mafodotin. Belinostat The serum concentration of Binimetinib can be increased when it is combined with Belinostat. Belumosudil The serum concentration of Binimetinib can be increased when it is combined with Belumosudil. Bendamustine The metabolism of Binimetinib can be decreased when combined with Bendamustine. Benzocaine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Benzyl alcohol. Berotralstat The serum concentration of Binimetinib can be increased when it is combined with Berotralstat. Betaxolol The metabolism of Binimetinib can be decreased when combined with Betaxolol. Betrixaban The serum concentration of Binimetinib can be increased when it is combined with Betrixaban. Bimekizumab The metabolism of Binimetinib can be increased when combined with Bimekizumab. Bisoprolol The serum concentration of Binimetinib can be increased when it is combined with Bisoprolol. Bortezomib The metabolism of Binimetinib can be decreased when combined with Bortezomib. Bromazepam The metabolism of Binimetinib can be decreased when combined with Bromazepam. Bromotheophylline The metabolism of Bromotheophylline can be decreased when combined with Binimetinib. Bupivacaine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Bupivacaine. Butacaine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Butamben. Cabazitaxel The serum concentration of Binimetinib can be increased when it is combined with Cabazitaxel. Caffeine The metabolism of Binimetinib can be decreased when combined with Caffeine. Canagliflozin The serum concentration of Binimetinib can be increased when it is combined with Canagliflozin. Canakinumab The metabolism of Binimetinib can be increased when combined with Canakinumab. Cannabidiol The metabolism of Binimetinib can be decreased when combined with Cannabidiol. Capmatinib The serum concentration of Binimetinib can be increased when it is combined with Capmatinib. Capsaicin The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Capsaicin. Carbamazepine The metabolism of Binimetinib can be increased when combined with Carbamazepine. Carfilzomib The serum concentration of Binimetinib can be increased when it is combined with Carfilzomib. Carmustine The metabolism of Binimetinib can be decreased when combined with Carmustine. Carvedilol The serum concentration of Binimetinib can be increased when it is combined with Carvedilol. Ceritinib The serum concentration of Binimetinib can be increased when it is combined with Ceritinib. Certolizumab pegol The metabolism of Binimetinib can be increased when combined with Certolizumab pegol. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Chloroprocaine. Chlorpromazine The metabolism of Binimetinib can be decreased when combined with Chlorpromazine. Chlorzoxazone The metabolism of Binimetinib can be decreased when combined with Chlorzoxazone. Cilostazol The metabolism of Binimetinib can be decreased when combined with Cilostazol. Cimetidine The metabolism of Binimetinib can be decreased when combined with Cimetidine. Cinacalcet The metabolism of Binimetinib can be decreased when combined with Cinacalcet. Cinchocaine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Cinchocaine. Cinnarizine The metabolism of Binimetinib can be decreased when combined with Cinnarizine. Cinoxacin The metabolism of Binimetinib can be decreased when combined with Cinoxacin. Ciprofloxacin The metabolism of Binimetinib can be decreased when combined with Ciprofloxacin. Citalopram The metabolism of Binimetinib can be decreased when combined with Citalopram. Clarithromycin The serum concentration of Binimetinib can be increased when it is combined with Clarithromycin. Clobazam The serum concentration of Binimetinib can be increased when it is combined with Clobazam. Clofazimine The serum concentration of Binimetinib can be increased when it is combined with Clofazimine. Clomifene The serum concentration of Binimetinib can be increased when it is combined with Clomifene. Clomipramine The metabolism of Binimetinib can be decreased when combined with Clomipramine. Clonidine The metabolism of Binimetinib can be decreased when combined with Clonidine. Clopidogrel The metabolism of Binimetinib can be decreased when combined with Clopidogrel. Clozapine The metabolism of Binimetinib can be decreased when combined with Clozapine. Cobicistat The serum concentration of Binimetinib can be increased when it is combined with Cobicistat. Cobimetinib The serum concentration of Binimetinib can be increased when it is combined with Cobimetinib. Cocaine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Cocaine. Colchicine The serum concentration of Binimetinib can be increased when it is combined with Colchicine. Conivaptan The serum concentration of Binimetinib can be increased when it is combined with Conivaptan. Conjugated estrogens The metabolism of Binimetinib can be decreased when combined with Conjugated estrogens. Copanlisib The serum concentration of Binimetinib can be increased when it is combined with Copanlisib. Crizotinib The serum concentration of Binimetinib can be increased when it is combined with Crizotinib. Curcumin The serum concentration of Binimetinib can be increased when it is combined with Curcumin. Cyclobenzaprine The metabolism of Binimetinib can be decreased when combined with Cyclobenzaprine. Cyclosporine The serum concentration of Binimetinib can be increased when it is combined with Cyclosporine. Cyproterone acetate The metabolism of Binimetinib can be increased when combined with Cyproterone acetate. Dabigatran etexilate The serum concentration of Binimetinib can be increased when it is combined with Dabigatran etexilate. Dabrafenib The metabolism of Binimetinib can be decreased when combined with Dabrafenib. Dacarbazine The metabolism of Binimetinib can be decreased when combined with Dacarbazine. Daclatasvir The serum concentration of Binimetinib can be increased when it is combined with Daclatasvir. Dacomitinib The serum concentration of Binimetinib can be increased when it is combined with Dacomitinib. Dactinomycin The serum concentration of Binimetinib can be increased when it is combined with Dactinomycin. Dapagliflozin The metabolism of Binimetinib can be decreased when combined with Dapagliflozin. Daptomycin The serum concentration of Binimetinib can be increased when it is combined with Daptomycin. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Binimetinib. Darolutamide The serum concentration of Binimetinib can be increased when it is combined with Darolutamide. Darunavir The serum concentration of Binimetinib can be increased when it is combined with Darunavir. Dasabuvir The metabolism of Binimetinib can be decreased when combined with Dasabuvir. Dasatinib The metabolism of Binimetinib can be decreased when combined with Dasatinib. Deferasirox The serum concentration of Binimetinib can be increased when it is combined with Deferasirox. Desogestrel The metabolism of Binimetinib can be increased when combined with Desogestrel. Dexamethasone acetate The serum concentration of Binimetinib can be decreased when it is combined with Dexamethasone acetate. Dexfenfluramine The metabolism of Binimetinib can be decreased when combined with Dexfenfluramine. Dexmedetomidine The metabolism of Binimetinib can be decreased when combined with Dexmedetomidine. Diacerein The metabolism of Binimetinib can be decreased when combined with Diacerein. Diclofenac The metabolism of Binimetinib can be decreased when combined with Diclofenac. Digitoxin The serum concentration of Binimetinib can be increased when it is combined with Digitoxin. Digoxin The serum concentration of Binimetinib can be increased when it is combined with Digoxin. Dihydralazine The metabolism of Binimetinib can be decreased when combined with Dihydralazine. Diosmin The serum concentration of Binimetinib can be increased when it is combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Diphenhydramine. Disopyramide The metabolism of Binimetinib can be decreased when combined with Disopyramide. Dolutegravir The serum concentration of Binimetinib can be increased when it is combined with Dolutegravir. Domperidone The metabolism of Binimetinib can be decreased when combined with Domperidone. Dosulepin The metabolism of Binimetinib can be decreased when combined with Dosulepin. Doxepin The metabolism of Binimetinib can be decreased when combined with Doxepin. Dronabinol The metabolism of Binimetinib can be decreased when combined with Dronabinol. Dronedarone The serum concentration of Binimetinib can be increased when it is combined with Dronedarone. Duvelisib The serum concentration of Binimetinib can be increased when it is combined with Duvelisib. Dyclonine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Dyclonine. Edoxaban The serum concentration of Binimetinib can be increased when it is combined with Edoxaban. Efavirenz The metabolism of Binimetinib can be increased when combined with Efavirenz. Elagolix The serum concentration of Binimetinib can be increased when it is combined with Elagolix. Elbasvir The serum concentration of Binimetinib can be increased when it is combined with Elbasvir. Eliglustat The serum concentration of Binimetinib can be increased when it is combined with Eliglustat. Eltrombopag The metabolism of Binimetinib can be decreased when combined with Eltrombopag. Emapalumab The metabolism of Binimetinib can be increased when combined with Emapalumab. Enasidenib The serum concentration of Binimetinib can be increased when it is combined with Enasidenib. Enfortumab vedotin The serum concentration of Binimetinib can be increased when it is combined with Enfortumab vedotin. Enoxacin The metabolism of Binimetinib can be decreased when combined with Enoxacin. Entecavir The metabolism of Binimetinib can be decreased when combined with Entecavir. Entrectinib The serum concentration of Binimetinib can be increased when it is combined with Entrectinib. Erdafitinib The serum concentration of Binimetinib can be increased when it is combined with Erdafitinib. Erlotinib The metabolism of Binimetinib can be decreased when combined with Erlotinib. Ertugliflozin The metabolism of Binimetinib can be decreased when combined with Ertugliflozin. Erythromycin The serum concentration of Binimetinib can be increased when it is combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Binimetinib. Estradiol The metabolism of Binimetinib can be decreased when combined with Estradiol. Estradiol acetate The metabolism of Binimetinib can be decreased when combined with Estradiol acetate. Estradiol benzoate The metabolism of Estradiol benzoate can be decreased when combined with Binimetinib. Estradiol cypionate The metabolism of Estradiol cypionate can be decreased when combined with Binimetinib. Estradiol dienanthate The metabolism of Estradiol dienanthate can be decreased when combined with Binimetinib. Estradiol valerate The metabolism of Estradiol valerate can be decreased when combined with Binimetinib. Estrone sulfate The metabolism of Binimetinib can be decreased when combined with Estrone sulfate. Etanercept The metabolism of Binimetinib can be increased when combined with Etanercept. Ethambutol The metabolism of Binimetinib can be decreased when combined with Ethambutol. Ethanol The metabolism of Binimetinib can be decreased when combined with Ethanol. Ethinylestradiol The metabolism of Binimetinib can be increased when combined with Ethinylestradiol. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Etidocaine. Etoposide The metabolism of Binimetinib can be decreased when combined with Etoposide. Etoricoxib The metabolism of Binimetinib can be decreased when combined with Etoricoxib. Everolimus The serum concentration of Binimetinib can be increased when it is combined with Everolimus. Famotidine The metabolism of Binimetinib can be decreased when combined with Famotidine. Favipiravir The serum concentration of Binimetinib can be increased when it is combined with Favipiravir. Fedratinib The serum concentration of Binimetinib can be increased when it is combined with Fedratinib. Fenfluramine The metabolism of Binimetinib can be decreased when combined with Fenfluramine. Fexinidazole The metabolism of Binimetinib can be decreased when combined with Fexinidazole. Fexofenadine The serum concentration of Binimetinib can be increased when it is combined with Fexofenadine. Filgotinib The serum concentration of Binimetinib can be increased when it is combined with Filgotinib. Flecainide The metabolism of Binimetinib can be decreased when combined with Flecainide. Flibanserin The serum concentration of Binimetinib can be increased when it is combined with Flibanserin. Fluconazole The serum concentration of Binimetinib can be increased when it is combined with Fluconazole. Flunarizine The metabolism of Binimetinib can be decreased when combined with Flunarizine. Flunitrazepam The metabolism of Binimetinib can be decreased when combined with Flunitrazepam. Fluorouracil The metabolism of Binimetinib can be decreased when combined with Fluorouracil. Fluoxetine The metabolism of Binimetinib can be decreased when combined with Fluoxetine. Flurbiprofen The metabolism of Binimetinib can be decreased when combined with Flurbiprofen. Flutamide The metabolism of Binimetinib can be decreased when combined with Flutamide. Fluvoxamine The metabolism of Binimetinib can be decreased when combined with Fluvoxamine. Fosphenytoin The metabolism of Binimetinib can be increased when combined with Fosphenytoin. Fostamatinib The metabolism of Binimetinib can be decreased when combined with Fostamatinib. Fostemsavir The serum concentration of Binimetinib can be increased when it is combined with Fostemsavir. Frovatriptan The metabolism of Binimetinib can be decreased when combined with Frovatriptan. Futibatinib The serum concentration of Binimetinib can be increased when it is combined with Futibatinib. Gatifloxacin The metabolism of Binimetinib can be decreased when combined with Gatifloxacin. Gemcitabine The serum concentration of Binimetinib can be increased when it is combined with Gemcitabine. Gemfibrozil The metabolism of Binimetinib can be decreased when combined with Gemfibrozil. Gemifloxacin The metabolism of Binimetinib can be decreased when combined with Gemifloxacin. Gilteritinib The serum concentration of Binimetinib can be increased when it is combined with Gilteritinib. Givosiran The serum concentration of Binimetinib can be increased when it is combined with Givosiran. Glasdegib The serum concentration of Binimetinib can be increased when it is combined with Glasdegib. Glecaprevir The serum concentration of Binimetinib can be increased when it is combined with Glecaprevir. Golimumab The metabolism of Binimetinib can be increased when combined with Golimumab. Grazoprevir The serum concentration of Binimetinib can be increased when it is combined with Grazoprevir. Grepafloxacin The metabolism of Binimetinib can be decreased when combined with Grepafloxacin. Guanabenz The metabolism of Binimetinib can be decreased when combined with Guanabenz. Haloperidol The metabolism of Binimetinib can be decreased when combined with Haloperidol. Idelalisib The serum concentration of Binimetinib can be increased when it is combined with Idelalisib. Imatinib The metabolism of Binimetinib can be decreased when combined with Imatinib. Imipramine The metabolism of Binimetinib can be decreased when combined with Imipramine. Indacaterol The serum concentration of Binimetinib can be increased when it is combined with Indacaterol. Indinavir The metabolism of Binimetinib can be decreased when combined with Indinavir. Indomethacin The metabolism of Binimetinib can be decreased when combined with Indomethacin. Infliximab The metabolism of Binimetinib can be increased when combined with Infliximab. Inotuzumab ozogamicin The serum concentration of Binimetinib can be increased when it is combined with Inotuzumab ozogamicin. Insulin beef The metabolism of Binimetinib can be increased when combined with Insulin beef. Insulin pork The metabolism of Binimetinib can be increased when combined with Insulin pork. Interferon alfa-2a The metabolism of Binimetinib can be decreased when combined with Interferon alfa-2a. Interferon alfa-2b The metabolism of Binimetinib can be decreased when combined with Interferon alfa-2b. Interferon alfa-n1 The metabolism of Binimetinib can be decreased when combined with Interferon alfa-n1. Interferon alfa-n3 The metabolism of Binimetinib can be decreased when combined with Interferon alfa-n3. Interferon alfacon-1 The metabolism of Binimetinib can be decreased when combined with Interferon alfacon-1. Interferon beta-1a The metabolism of Binimetinib can be decreased when combined with Interferon beta-1a. Interferon beta-1b The metabolism of Binimetinib can be decreased when combined with Interferon beta-1b. Interferon gamma-1b The metabolism of Binimetinib can be decreased when combined with Interferon gamma-1b. Isavuconazole The serum concentration of Binimetinib can be increased when it is combined with Isavuconazole. Isavuconazonium The serum concentration of Binimetinib can be increased when it is combined with Isavuconazonium. Isoniazid The metabolism of Binimetinib can be decreased when combined with Isoniazid. Istradefylline The serum concentration of Binimetinib can be increased when it is combined with Istradefylline. Itraconazole The serum concentration of Binimetinib can be increased when it is combined with Itraconazole. Ivacaftor The serum concentration of Binimetinib can be increased when it is combined with Ivacaftor. Ixabepilone The serum concentration of Binimetinib can be increased when it is combined with Ixabepilone. Ketoconazole The serum concentration of Binimetinib can be increased when it is combined with Ketoconazole. Lamotrigine The metabolism of Binimetinib can be increased when combined with Lamotrigine. Lapatinib The serum concentration of Binimetinib can be increased when it is combined with Lapatinib. Larotrectinib The serum concentration of Binimetinib can be increased when it is combined with Larotrectinib. Lasmiditan The serum concentration of Binimetinib can be increased when it is combined with Lasmiditan. Ledipasvir The serum concentration of Binimetinib can be increased when it is combined with Ledipasvir. Lefamulin The serum concentration of Binimetinib can be increased when it is combined with Lefamulin. Leflunomide The serum concentration of Binimetinib can be decreased when it is combined with Leflunomide. Lemborexant The serum concentration of Binimetinib can be increased when it is combined with Lemborexant. Lenvatinib The serum concentration of Binimetinib can be increased when it is combined with Lenvatinib. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Levobupivacaine. Levoketoconazole The serum concentration of Binimetinib can be increased when it is combined with Levoketoconazole. Levothyroxine The serum concentration of Binimetinib can be decreased when it is combined with Levothyroxine. Lidocaine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Lidocaine. Linagliptin The serum concentration of Binimetinib can be increased when it is combined with Linagliptin. Lofexidine The metabolism of Binimetinib can be decreased when combined with Lofexidine. Lomefloxacin The metabolism of Binimetinib can be decreased when combined with Lomefloxacin. Lomitapide The serum concentration of Binimetinib can be increased when it is combined with Lomitapide. Lonafarnib The serum concentration of Binimetinib can be increased when it is combined with Lonafarnib. Lonapegsomatropin The metabolism of Binimetinib can be increased when combined with Lonapegsomatropin. Loncastuximab tesirine The serum concentration of Binimetinib can be increased when it is combined with Loncastuximab tesirine. Loperamide The serum concentration of Binimetinib can be increased when it is combined with Loperamide. Lopinavir The serum concentration of Binimetinib can be increased when it is combined with Lopinavir. Lorcaserin The metabolism of Binimetinib can be decreased when combined with Lorcaserin. Lorlatinib The serum concentration of Binimetinib can be decreased when it is combined with Lorlatinib. Loxapine The serum concentration of Binimetinib can be increased when it is combined with Loxapine. Lumacaftor The serum concentration of Binimetinib can be decreased when it is combined with Lumacaftor. Lusutrombopag The serum concentration of Binimetinib can be increased when it is combined with Lusutrombopag. Mannitol The serum concentration of Binimetinib can be increased when it is combined with Mannitol. Maprotiline The metabolism of Binimetinib can be decreased when combined with Maprotiline. Maribavir The serum concentration of Binimetinib can be increased when it is combined with Maribavir. Mefenamic acid The metabolism of Binimetinib can be decreased when combined with Mefenamic acid. Mefloquine The serum concentration of Binimetinib can be increased when it is combined with Mefloquine. Melatonin The metabolism of Binimetinib can be decreased when combined with Melatonin. Meloxicam The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Meloxicam. Mephenytoin The metabolism of Binimetinib can be decreased when combined with Mephenytoin. Mepivacaine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Mepivacaine. Methimazole The metabolism of Binimetinib can be decreased when combined with Methimazole. Methoxsalen The metabolism of Binimetinib can be decreased when combined with Methoxsalen. Methoxy polyethylene The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Binimetinib. Methylene blue The serum concentration of Binimetinib can be increased when it is combined with Methylene blue. Metoclopramide The metabolism of Binimetinib can be decreased when combined with Metoclopramide. Mexiletine The metabolism of Binimetinib can be decreased when combined with Mexiletine. Mianserin The metabolism of Binimetinib can be decreased when combined with Mianserin. Mifepristone The serum concentration of Binimetinib can be decreased when it is combined with Mifepristone. Mirabegron The serum concentration of Binimetinib can be increased when it is combined with Mirabegron. Mirtazapine The metabolism of Binimetinib can be decreased when combined with Mirtazapine. Mitapivat The metabolism of Binimetinib can be increased when combined with Mitapivat. Morphine The serum concentration of Binimetinib can be increased when it is combined with Morphine. Moxifloxacin The metabolism of Binimetinib can be decreased when combined with Moxifloxacin. Nabumetone The metabolism of Binimetinib can be decreased when combined with Nabumetone. Nafcillin The metabolism of Binimetinib can be increased when combined with Nafcillin. Nalidixic acid The metabolism of Binimetinib can be decreased when combined with Nalidixic acid. Naproxen The metabolism of Binimetinib can be decreased when combined with Naproxen. Nelfinavir The metabolism of Binimetinib can be increased when combined with Nelfinavir. Neratinib The serum concentration of Binimetinib can be increased when it is combined with Neratinib. Netupitant The serum concentration of Binimetinib can be increased when it is combined with Netupitant. Nevirapine The metabolism of Binimetinib can be decreased when combined with Nevirapine. Niclosamide The metabolism of Binimetinib can be decreased when combined with Niclosamide. Nifedipine The metabolism of Binimetinib can be decreased when combined with Nifedipine. Nilotinib The serum concentration of Binimetinib can be increased when it is combined with Nilotinib. Nintedanib The serum concentration of Binimetinib can be increased when it is combined with Nintedanib. Norfloxacin The metabolism of Binimetinib can be decreased when combined with Norfloxacin. Norgestimate The serum concentration of Binimetinib can be increased when it is combined with Norgestimate. Obeticholic acid The metabolism of Binimetinib can be decreased when combined with Obeticholic acid. Olanzapine The metabolism of Binimetinib can be decreased when combined with Olanzapine. Omadacycline The serum concentration of Binimetinib can be increased when it is combined with Omadacycline. Ombitasvir The metabolism of Binimetinib can be decreased when combined with Ombitasvir. Omeprazole The metabolism of Binimetinib can be increased when combined with Omeprazole. Ondansetron The metabolism of Binimetinib can be decreased when combined with Ondansetron. Orphenadrine The metabolism of Binimetinib can be decreased when combined with Orphenadrine. Osilodrostat The metabolism of Binimetinib can be decreased when combined with Osilodrostat. Osimertinib The serum concentration of Binimetinib can be decreased when it is combined with Osimertinib. Oxetacaine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Oxetacaine. Oxtriphylline The metabolism of Binimetinib can be decreased when combined with Oxtriphylline. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Oxybuprocaine. Pacritinib The serum concentration of Binimetinib can be increased when it is combined with Pacritinib. Palbociclib The serum concentration of Binimetinib can be increased when it is combined with Palbociclib. Paliperidone The serum concentration of Binimetinib can be increased when it is combined with Paliperidone. Panobinostat The serum concentration of Binimetinib can be increased when it is combined with Panobinostat. Paritaprevir The metabolism of Binimetinib can be decreased when combined with Paritaprevir. Paroxetine The metabolism of Binimetinib can be decreased when combined with Paroxetine. Pazopanib The metabolism of Binimetinib can be decreased when combined with Pazopanib. Pefloxacin The metabolism of Binimetinib can be decreased when combined with Pefloxacin. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Binimetinib. Peginterferon alfa-2a The metabolism of Binimetinib can be decreased when combined with Peginterferon alfa-2a. Peginterferon alfa-2b The serum concentration of Binimetinib can be increased when it is combined with Peginterferon alfa-2b. Pemetrexed The metabolism of Binimetinib can be decreased when combined with Pemetrexed. Penciclovir The metabolism of Binimetinib can be decreased when combined with Penciclovir. Pentoxifylline The metabolism of Binimetinib can be decreased when combined with Pentoxifylline. Perampanel The metabolism of Binimetinib can be decreased when combined with Perampanel. Perphenazine The metabolism of Binimetinib can be decreased when combined with Perphenazine. Pexidartinib The metabolism of Binimetinib can be decreased when combined with Pexidartinib. Phenobarbital The metabolism of Binimetinib can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Phenol. Phenylephrine The metabolism of Binimetinib can be increased when combined with Phenylephrine. Phenytoin The metabolism of Binimetinib can be increased when combined with Phenytoin. Pibrentasvir The serum concentration of Binimetinib can be increased when it is combined with Pibrentasvir. Pimozide The metabolism of Binimetinib can be decreased when combined with Pimozide. Pirfenidone The metabolism of Binimetinib can be decreased when combined with Pirfenidone. Pitolisant The metabolism of Binimetinib can be increased when combined with Pitolisant. Pomalidomide The metabolism of Binimetinib can be decreased when combined with Pomalidomide. Ponatinib The serum concentration of Binimetinib can be increased when it is combined with Ponatinib. Posaconazole The serum concentration of Binimetinib can be increased when it is combined with Posaconazole. Pralsetinib The serum concentration of Binimetinib can be increased when it is combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Pramocaine. Pravastatin The serum concentration of Binimetinib can be increased when it is combined with Pravastatin. Praziquantel The metabolism of Binimetinib can be decreased when combined with Praziquantel. Prednisolone The serum concentration of Binimetinib can be decreased when it is combined with Prednisolone phosphate. Prilocaine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Prilocaine. Primaquine The metabolism of Binimetinib can be increased when combined with Primaquine. Primidone The metabolism of Binimetinib can be increased when combined with Primidone. Probenecid The metabolism of Binimetinib can be decreased when combined with Probenecid. Procaine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Procaine. Promazine The metabolism of Binimetinib can be decreased when combined with Promazine. Propafenone The serum concentration of Binimetinib can be increased when it is combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Proparacaine. Propofol The metabolism of Binimetinib can be decreased when combined with Propofol. Propoxycaine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Propoxycaine. Propranolol The metabolism of Binimetinib can be decreased when combined with Propranolol. Quinidine The serum concentration of Binimetinib can be increased when it is combined with Quinidine. Quinine The serum concentration of Binimetinib can be increased when it is combined with Quinine. Ramelteon The metabolism of Binimetinib can be decreased when combined with Ramelteon. Ranitidine The metabolism of Binimetinib can be decreased when combined with Ranitidine. Ranolazine The serum concentration of Binimetinib can be increased when it is combined with Ranolazine. Rasagiline The metabolism of Binimetinib can be decreased when combined with Rasagiline. Regorafenib The serum concentration of Binimetinib can be increased when it is combined with Regorafenib. Relugolix The serum concentration of Binimetinib can be increased when it is combined with Relugolix. Reserpine The serum concentration of Binimetinib can be increased when it is combined with Reserpine. Revefenacin The serum concentration of Binimetinib can be increased when it is combined with Revefenacin. Rifampicin The serum concentration of Binimetinib can be decreased when it is combined with Rifampicin. Rifamycin The serum concentration of Binimetinib can be increased when it is combined with Rifamycin. Rilonacept The metabolism of Binimetinib can be increased when combined with Rilonacept. Riluzole The metabolism of Binimetinib can be decreased when combined with Riluzole. Rimegepant The serum concentration of Binimetinib can be increased when it is combined with Rimegepant. Riociguat The serum concentration of Binimetinib can be increased when it is combined with Riociguat. Ripretinib The serum concentration of Binimetinib can be increased when it is combined with Ripretinib. Ritonavir The serum concentration of Binimetinib can be increased when it is combined with Ritonavir. Rivaroxaban The serum concentration of Binimetinib can be increased when it is combined with Rivaroxaban. Rofecoxib The metabolism of Binimetinib can be decreased when combined with Rofecoxib. Roflumilast The metabolism of Binimetinib can be decreased when combined with Roflumilast. Rolapitant The serum concentration of Binimetinib can be increased when it is combined with Rolapitant. Romidepsin The serum concentration of Binimetinib can be increased when it is combined with Romidepsin. Ropeginterferon alfa-2b The metabolism of Binimetinib can be decreased when combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Ropivacaine. Rosoxacin The metabolism of Binimetinib can be decreased when combined with Rosoxacin. Rucaparib The metabolism of Binimetinib can be increased when combined with Rucaparib. Sapropterin The serum concentration of Binimetinib can be increased when it is combined with Sapropterin. Saquinavir The serum concentration of Binimetinib can be increased when it is combined with Saquinavir. Sarecycline The serum concentration of Binimetinib can be increased when it is combined with Sarecycline. Satralizumab The serum concentration of Binimetinib can be decreased when it is combined with Satralizumab. Secukinumab The metabolism of Binimetinib can be increased when combined with Secukinumab. Selegiline The metabolism of Binimetinib can be decreased when combined with Selegiline. Selexipag The serum concentration of Binimetinib can be increased when it is combined with Selexipag. Selumetinib The metabolism of Binimetinib can be decreased when combined with Selumetinib. Sildenafil The serum concentration of Binimetinib can be increased when it is combined with Sildenafil. Silodosin The serum concentration of Binimetinib can be increased when it is combined with Silodosin. Siltuximab The metabolism of Binimetinib can be increased when combined with Siltuximab. Simeprevir The serum concentration of Binimetinib can be increased when it is combined with Simeprevir. Simvastatin The serum concentration of Binimetinib can be increased when it is combined with Simvastatin. Sirolimus The serum concentration of Binimetinib can be increased when it is combined with Sirolimus. Sitagliptin The serum concentration of Binimetinib can be increased when it is combined with Sitagliptin. Sodium aurothiomalate The metabolism of Binimetinib can be decreased when combined with Sodium aurothiomalate. Sofosbuvir The serum concentration of Binimetinib can be increased when it is combined with Sofosbuvir. Somapacitan The metabolism of Binimetinib can be increased when combined with Somapacitan. Somatotropin The metabolism of Binimetinib can be increased when combined with Somatotropin. Somatrem The metabolism of Binimetinib can be increased when combined with Somatrem. Somatrogon The metabolism of Binimetinib can be increased when combined with Somatrogon. Sorafenib The serum concentration of Binimetinib can be increased when it is combined with Sorafenib. Sotagliflozin The serum concentration of Binimetinib can be increased when it is combined with Sotagliflozin. Sotorasib The serum concentration of Binimetinib can be increased when it is combined with Sotorasib. St. John's Wort The serum concentration of Binimetinib can be decreased when it is combined with St. John's Wort. Stiripentol The serum concentration of Binimetinib can be increased when it is combined with Stiripentol. Suvorexant The serum concentration of Binimetinib can be increased when it is combined with Suvorexant. Tacrine The metabolism of Binimetinib can be decreased when combined with Tacrine. Tacrolimus The serum concentration of Binimetinib can be increased when it is combined with Tacrolimus. Pregnancy and Lactation US FDA pregnancy category Not Assigned Pregnancy Drugs that have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details. The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help healthcare providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out. Lactation No information is available on the use of this drug during breastfeeding. Because it is highly bound to plasma proteins, and the half-life is 3.5 hours, the amount in milk is likely to be low; however, the manufacturer recommends that breastfeeding be discontinued during therapy and for at least 3 days after. For patients taking the combination with encorafenib, the manufacturer recommends that breastfeeding be discontinued during therapy and for at least 2 weeks after. How should this medicine be used?

Binimetinib comes as a tablet to take by mouth. It is usually taken with or without food twice daily, approximately 12 hours apart. Take binimetinib at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take binimetinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. If you vomit…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)